Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Application of glutaminase inhibitor in preparation of medicine for treating psoriasis

A technology of glutaminase and inhibitors, applied in the field of medicine, can solve the problems of small psoriasis drugs lacking side effects, and the treatment effect is not completely satisfactory.

Inactive Publication Date: 2020-09-11
GUANGDONG HOSPITAL OF TRADITIONAL CHINESE MEDICINE
View PDF5 Cites 8 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

Although there are many drug treatment options for psoriasis at present, the therapeutic effect is still not completely satisfactory, and there is still a lack of a drug for the treatment of psoriasis with significant curative effect and small side effects in the prior art.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Application of glutaminase inhibitor in preparation of medicine for treating psoriasis
  • Application of glutaminase inhibitor in preparation of medicine for treating psoriasis
  • Application of glutaminase inhibitor in preparation of medicine for treating psoriasis

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1CB-839

[0044] Example 1 CB-839 inhibits the uptake and metabolism of keratinocyte glutamine

[0045] Add 10 μM CB-839 (CB-839 group) and equal volume of DMSO (Ctrl group) to the culture medium of keratinocyte HaCaT cells respectively, after 12 hours of intervention, collect the cell culture medium, and use the method of targeted metabolomics Detect the contents of glutamine (glutamine) and glutamic acid (glutamate) in the collected cell culture fluid, and by comparing with fresh culture fluid, calculate the amount of glutamine (ie glutamine) taken up by cells under different intervention conditions. consumption of amide) and the amount of glutamic acid secreted into the cell culture medium (i.e. the secretion of glutamic acid), the results are as follows Figure 1-2 shown. Depend on Figure 1-2 The results showed that CB-839 can significantly inhibit the uptake of glutamine by keratinocytes (P<0.001), and reduce the amount of glutamic acid secreted by keratinocytes into the culture...

Embodiment 2

[0048] Example 2 CB-839 inhibits miR-31-induced mitochondrial respiration of keratinocytes

[0049] Oxygen consumption rate (OCR) is the oxygen consumption rate of cells, which is an indicator of mitochondrial respiration capacity. Oxygen consumption detection principle: The value displayed before adding oligo represents the basic oxygen consumption of cells, including mitochondrial oxidative phosphorylation and proton leakage oxygen consumption, that is, after protons pass through the mitochondrial membrane to form potential energy through the respiratory chain, a part Proton reflux can form ATP by ATP synthase, which converts potential energy into energy in ATP. A portion passes through the mitochondrial membrane but is only oxidized, and the potential energy is converted into heat, but not used to synthesize ATP. Oligo is an ATP synthase inhibitor. The reduced oxygen consumption after adding this drug represents the oxygen consumption used by the body for ATP synthesis, an...

Embodiment 3

[0052] Example 3 Western Blotting Experiment of CB-839 Inhibiting the mTOR Pathway Induced by miR-31

[0053] Western Blotting experiments can detect the expression of the target protein. 24 hours after HaCaT cells were transfected with control miRNAmimic or miR-31mimic, they were intervened with DMSO and 10 μM CB-839; among them, those who were given DMSO intervention 24 hours after transfection with control miRNAmimic were recorded as the Ctrl-mimic group, and those transfected with miR-31mimic for 24 hours The miR-31mimic group was given after DMSO intervention, the CB839 group was given 10 μM CB-839 intervention 24 hours after transfection of control miRNA mimic, and the miR-31mimic group was given 10 μM CB-839 intervention 24 hours after miR-31mimic transfection. -31+CB839 group. In addition, HaCaT cells were transfected with control siRNA (ThermoFisher Scientific, AM4635) and GS-siRNA (ThermoFisher Scientific, AM16708) 24 hours after each intervention with DMSO as a con...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention discloses application of a glutaminase inhibitor in preparation of a medicine for treating psoriasis. In-vitro cell experiments prove that the glutaminase inhibitor can inhibit keratinocyte metabolism glutamine, inhibit miR-31 induced up-regulated keratinocyte mitochondrial respiration, inhibit miR-31 induced mTOR pathway, reduce cell activity and promote cell apoptosis, and has an anti-inflammatory effect; animal experiments prove that the glutaminase inhibitor can be used for effectively treating imiquimod-induced mouse psoriasis-like pathology change, including remarkably reducing the Baker score of skin lesion, effectively reducing the epidermal hypertrophy degree, remarkably reducing the number of subepidermal capillaries, remarkably reducing the number of epidermal Ki67positive cells and reducing the expression of epidermal GLS. Therefore, the glutaminase inhibitor can be used for preparing the medicine for treating psoriasis.

Description

technical field [0001] The invention belongs to the technical field of medicine and relates to the use of glutaminase inhibitors, in particular to the application of glutaminase inhibitors in the preparation of medicines for treating psoriasis. Background technique [0002] Psoriasis is a chronic inflammatory skin disease with skin erythema, papules, and scales as the main clinical manifestations, and the global incidence is about 1-3%. The main pathological features of psoriasis are excessive epidermis proliferation and local inflammatory cell infiltration, and the metabolic spectrum of local skin lesions changes. The pathogenesis is complex, involving genetics, immune-inflammation, vascular abnormalities, etc. Procrastination is hard to heal. Drugs currently used to treat psoriasis mainly include glucocorticoids, retinoic acid drugs, vitamin D3 derivatives, anthranol, cytotoxic drugs, etc. Among them, tazarotene, moderate and strong glucocorticoids Hormone and calcipotri...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): A61K45/00A61K31/42A61K31/501A61K31/473A61K31/433A61P17/06
CPCA61K45/00A61K31/42A61K31/501A61K31/473A61K31/433A61P17/06A61K2300/00
Inventor 卢传坚徐永跃王茂杰黄闰月包德威·伯格林焦琳
Owner GUANGDONG HOSPITAL OF TRADITIONAL CHINESE MEDICINE
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com